Second-Quarter Revenue Increased 74% to Record $12.2 Million

Record Gross Margins of 60.6% Mark Seventh Consecutive Quarter of 50%+ Margins

DAVIS, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) — Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio” or the “Company”), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, has provided its financial results for the second quarter ended June 30, 2020.

Selected Operating and Financial Highlights

$ in millions Q2
2020
Q2
2019
% Increase
(Decrease)
H1
2020
H1
2019
% Increase
(Decrease)
Revenues $12.2 $7.0 74% $21.8 $15.7 39%
Gross Profit $7.4 $3.8 94% $13.0 $8.8 47%
Gross Margin 60.6% 54.4% +620bps 59.3% 56.0% +330bps
Operating Expenses $9.4 $10.2 (8%) $20.6 $18.9 9%
Operating Expense Ratio 77% 146% -6,900bps 94% 120% -2,600bps
Net Income (Loss) ($2.9) ($6.8) (58%) ($9.9) ($10.7) (7%)
Adjusted EBITDA1 ($1.5) ($3.8) (61%) ($5.2) ($6.4) (18%)
Cash Used in Operations ($1.5) ($3.0) (52%) ($7.7) ($10.6) (27%)

1Adjusted EBITDA is a non-GAAP financial measure and is described in relation to its most directly comparable GAAP measure under “Use of Non-GAAP Financial Information” below.

Second Quarter 2020 Financial Summary

  • Revenues in the second quarter of 2020 increased 74% to an all-time record of $12.2 million, and the company’s eighth consecutive quarter of year-over-year growth.  The increase was driven by global sales in row crops, including Pro Farm’s UBP and Foramin seed treatments.  Sales in the specialty crop markets also contributed to the improvement, particularly from the family of Regalia fungicides and Venerate and Grandevo insecticides.
  • Gross margins in the second quarter of 2020 were 60.6%, the seventh consecutive quarter in which gross margins exceeded 50%.  The margin improvement reflected the mix of high-margin foliar and seed treatment products sold in the second quarter.  Second quarter 2020 gross profit of $7.4 million was nearly double gross profit of the same period in 2019.
     
  • Operating expenses in the second quarter of 2020 decreased 8% to $9.4 million, compared with $10.2 million in the comparable period in 2019.  Operating expenses benefited by $1.4 million from a Paycheck Protection Program (PPP) loan secured to retain employees supporting the essential agricultural industry during the COVID-19 pandemic.  Spending in the quarter also included the addition of operating expenses from the 2019 acquisition of Pro Farm.
     
  • The operating expense ratio – comparing operating expenses to revenues – was 77% in the second quarter of 2020, as compared with 146% in the second quarter of 2019.  The ratio improvement quarter-to-quarter reflected significant revenue growth coupled with cost savings efforts and the benefit of the PPP loan.
     
  • Net income (loss) in the second quarter of 2020 decreased 58% to a loss of $2.9 million, as compared with a net loss of $6.8 million in the second quarter of 2019.    The net loss in the quarter included non-cash adjustments for warrant exercises, stock compensation and the amortization of intangibles related to the Pro Farm acquisition.
     
  • Adjusted EBITDA improved by 61%, with a loss of $1.5 million in the second quarter of 2020 as compared with a loss of $3.8 million in the same period last year.  Record revenues and gross profit, plus lower operating expenses, drove the improvement in both the net loss and Adjusted EBITDA.  Adjusted EBITDA is further described under “Use of Non-GAAP Financial Information” below.
     
  • Cash used in operations in the second quarter was $1.5 million, a 52% decline from $3 million in the same period in 2019.  Cash used in operations in the quarter included $1.7 million in proceeds from the PPP loan.

First Half 2020 Financial Summary

  • Revenues in the first half of 2020 increased 39% to a record $21.8 million, as compared with $15.7 million in the first half of 2019.  The company achieved higher sales in the specialty crop markets, and benefited from its successful BioUnite program with products such as Regalia fungicide and Venerate insecticide.  First-half results also grew from sales in the row crop markets, particularly Pro Farm’s UBP and Foramin seed treatments.
     
  • Gross profit in the first half rose 47% to $13 million.  Gross margins increased by 330 basis points to 59.3%, reflecting product mix.
     
  • Operating expenses increased 9% to $20.6 million in the first half of 2020, compared with operating expenses of $18.9 million in the first half of 2019.  The increase was driven by the addition of six months of operating expenses from Pro Farm, somewhat offset by the benefit of $1.4 million from the PPP loan.
     
  • The operating expense ratio for the first half of 2020 was 94%, a 2,600 basis point improvement that reflected a higher rate of growth for revenues.
     
  • Net income (loss) in the first half decreased to a loss of $9.9 million, an improvement over the net loss of $10.7 million in the same period last year.  Record revenues and gross profit contributed to the improvement in net loss, somewhat offset by the increase in operating expenses, plus non-cash adjustments related to warrant exercises, stock compensation and amortization charges.
     
  • Adjusted EBITDA in the first half of 2020 was a loss of $5.2 million, an 18 percent improvement from an Adjusted EBITDA  loss of $6.4 million in the first half of 2019.  Adjusted EBITDA is further described under “Use of Non-GAAP Financial Information” below.
     
  • Cash used in operations in the first half was $7.7 million, a 27% decline from $10.6 million in the first half of 2019.  As in the second quarter, cash used in operations in the first half benefited from $1.7  million in proceeds from the PPP loan.

Management Commentary

“The second-quarter financial results highlight the momentum our team has created, as well as the opportunity to accelerate our commercial velocity and break out as a market leader,” said Chief Executive Officer Kevin Helash, who joined Marrone Bio effective August 3, 2020.  “Our goals to drive profitability are gaining traction as the company transforms itself into a top-tier commercial-scale player in the biological agriculture sector.

“This has been a strong start to the year, and it is the foundation from which we can leverage our base business, execute our expansion plans and broaden our global reach.  Coupled with a customer-centric culture, and a focus on the execution of our operational and financial objectives, I believe the path to profitability can be accelerated, which will, in turn, create enhanced shareholder value,” added Helash.

“We expect to drive continued revenue growth and international expansion in the second half of the year, with gross margins in line with achieving our annual target in the mid-50% range.   The integration of the Pro Farm acquisition is going very well, and is tracking to be accretive to net income and cash from operations this year, as we had forecast.   While we remain optimistic about the remainder of the fiscal year, plans remain in place for the potential effect that the COVID-19 pandemic may have on macro conditions in the agricultural sector,” Helash concluded.

Operational Highlights

  • Regalia® Maxx biofungicide received the first approval for indoor and outdoor use on cannabis and hemp in Canada, providing farmers an effective new tool to manage difficult diseases, such as botrytis and powdery mildew.
  • The company entered into a warrant exchange agreement with existing institutional investors, which, assuming exercise in full, is expected to provide adequate cash to reach cash flow breakeven under the company’s current operating plan.  The total number of outstanding warrants was reduced by approximately 35%, from 52.6 million to 36.5 million.  Expiration dates were significantly shortened ,with new warrants issued in five tranches, expiring by the end of 2021.
  • Entered into an agreement with Vive Crop Protection to offer a suite of ground-breaking products for U.S. growers that combines the active ingredient in Regalia® with a proven fungicide.  The pre-mix product also will contain Vive’s Allosperse Delivery System technology for use in multi applications in major crops, pending regulatory approvals.  The company will have rights to directly market a version of the product to specialty crop growers in California.

Conference Call and Webcast

Management will host an investor conference call today, August 10, 2020, at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss Marrone Bio Innovations’ 2020 second quarter financial results. The call will conclude with a Q&A from participants. To participate, please use the following information:

Q2 2020 Conference Call and Webcast
Date: Monday, August 10, 2020
Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time)
U.S. Dial-in: 1-866-248-8441
International Dial-in: 1-323-289-6576
Conference ID:  7510516
Webcast: http://public.viavid.com/index.php?id=140993

Please dial in at least 10 minutes before the start of the call to ensure timely participation.

A playback of the call will be available through September 10, 2020. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally. Please use the replay pin number 7510516. A webcast will also be available for 30 days on the IR section of the Marrone Bio Innovations website or by clicking here:  MBII Q2 2020 Webcast

About Marrone Bio Innovations     
Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented company leading the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies and natural product chemistry to rapidly develop seven product lines. Supported by a robust portfolio of over 400 issued and pending patents, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven®, Pacesetter™, Zelto® Jet Oxide® and Jet Ag® and Zequanox®, with a next-generation insecticide-nematicide, a breakthrough bioherbicide and a biofumigant in the Company’s product pipeline. MBI’s Pro Farm Finland-based subsidiary employs a proprietary technology derived from wood waste to stimulate plant growth and improve plant health, resulting in improved yields and crop quality. Products include UBP™ 110, Foramin®, UBP™ Seed Treatment, Foramin® ST.

Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram.

Non-GAAP Financial Measures                                                                                                                                                                                                        
This earnings release discusses Adjusted EBITDA which is not a financial measure as defined by GAAP. This financial measure is presented as a supplemental measure of operating performance because we believe it can aid in, and enhance, the understanding of our financial results. In addition, we use Adjusted EBITDA as a measure internally for budgeting purposes.

For a reconciliation of the non-GAAP measures presented in this earnings release to their most directly comparable financial measure prepared in accordance with GAAP, see “Non-GAAP Reconciliation” below. Other companies may define or calculate this measure differently, limiting the usefulness as a comparative measure. Because of this limitation, this non-GAAP financial measure should not be considered in isolation or as substitute for or superior to performance measures calculated in accordance with GAAP and should be read in conjunction with the financial statement tables.                                                                                                              
                                                                                                                       
We define Adjusted EBITDA as net income (loss) before (1) interest expense (income), net, (2) income tax expense (benefit), (3) depreciation, (4) amortization of intangible assets, (5) stock-based compensation expense, plus (6) from time to time, certain other items which are specific transaction-related items.

GAAP to non-GAAP Reconciliation                
(in thousands)                
    THREE MONTHS   THREE MONTHS   SIX MONTHS   SIX MONTHS
    ENDED   ENDED   ENDED   ENDED
    6/30/2020   6/30/2019   6/30/2020   6/30/2019
                 
Net Loss $ (2,870 ) $ (6,752 ) $ (9,894 ) $ (10,669 )
Income taxes   46         80      
Interest expense   331     353     668     659  
Depreciation and amortization   890     448     1,781     903  
Stock based compensation   884     606     1,791     1,164  
Acquisition related costs       1,054         1,054  
Litigation cost and settlement       509         509  
Loss on issuance of new warrants           1,391      
Change in fair value of contingent consideration   600         363      
Reduction in expenses related to PPP funds   (1,396 )       (1,396 )    
Adjusted EBITDA $ (1,515 ) $ (3,782 ) $ (5,216 ) $ (6,380 )

Marrone Bio Innovations Forward Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties.  All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date.  Examples of such statements include financial guidance and other statements regarding the Company’s future financial results and revenue growth, future adoption of the Company’s products, plans for accelerating commercial velocity, the potential benefits of recent acquisitions and the Company’s products, and the potential future exercise of the Company’s warrants. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including the recent uncertainty in the global economy and industry-specific economy caused by the COVID-19 pandemic, consumer, regulatory and other factors affecting demand for the Company’s products, any difficulty in marketing MBI’s products in global markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, adverse decisions by regulatory agencies and other relevant third parties and any difficulty in integrating the acquired Pro Farm, Jet-Ag and Jet-Oxide businesses.  Additional information that could lead to material changes in MBI’s performance is contained in its filings with the Securities and Exchange Commission.  MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise.

Marrone Bio Innovations Contacts:
Kevin Helash, CEO
Jim Boyd, President and CFO
Telephone: +1 (530) 750-2800
Email: Info@marronebio.com

Investor Relations:
Lucas A. Zimmerman
Senior Vice President
MZ Group – MZ North America
Main: 949-259-4987
MBII@mzgroup.us

MARRONE BIO INNOVATIONS, INC.
Condensed Consolidated Balance Sheets
(In Thousands, Except Par Value)

  JUNE 30,     DECEMBER 31,  
  2020     2019  
Assets              
Current assets:              
Cash and cash equivalents $ 10,451     $ 6,252  
Accounts receivable   11,437       5,925  
Inventories, net   6,139       8,149  
Prepaid expenses and other current assets   1,340       1,390  
Total current assets   29,367       21,716  
Property, plant and equipment, net   13,004       13,260  
Right of use assets, net   4,173       4,567  
Intangible assets, net   22,666       23,842  
Goodwill   6,740       6,764  
Restricted cash   1,560       1,560  
Other assets   891       1,008  
Total assets $ 78,401     $ 72,717  
Liabilities and stockholders’ equity              
Current liabilities:              
Accounts payable $ 1,022     $ 3,379  
Accrued liabilities   14,439       12,467  
Deferred revenue, current portion   534       427  
Lease liability, current portion   957       913  
Debt, current portion, net   8,918       3,899  
Total current liabilities   25,870       21,085  
Deferred revenue, less current portion   1,816       1,986  
Lease liability, less current portion   3,529       3,970  
Debt, less current portion, net   11,447       11,847  
Debt due to related parties   7,300       7,300  
Other liabilities   2,338       2,971  
Total liabilities   52,300       49,159  
Commitments and contingencies              
Stockholders’ equity:              
Preferred stock: $0.00001 par value; 20,000 shares authorized and no shares issued or outstanding at June 30, 2020 and December 31, 2019          
Common stock: $0.00001 par value; 250,000 shares authorized, 149,362 and 139,526 shares issued and outstanding as of June 30, 2020 and December 31, 2019   1       1  
Additional paid in capital   356,643       344,206  
Accumulated deficit   (330,543 )     (320,649 )
Total stockholders’ equity   26,101       23,558  
Total liabilities and stockholders’ equity $ 78,401     $ 72,717  


MARRONE BIO INNOVATIONS, INC.
Condensed Consolidated Statements of Operations
(In Thousands, Except Per Share Amounts)
(Unaudited)

                       
  THREE MONTHS ENDED
JUNE 30,
    SIX MONTHS ENDED
JUNE 30,
 
  2020     2019     2020     2019  
Revenues:                      
Product $ 12,063     $ 6,882     $ 21,598     $ 15,483  
License   115       115       230       230  
Total revenues   12,178       6,997       21,828       15,713  
Cost of product revenues   4,794       3,188       8,875       6,917  
Gross profit   7,384       3,809       12,953       8,796  
Operating Expenses:                              
Research, development and patent   2,312       3,634       5,546       6,576  
Selling, general and administrative   7,078       6,604       15,071       12,278  
Total operating expenses   9,390       10,238       20,617       18,854  
Loss from operations   (2,006 )     (6,429 )     (7,664 )     (10,058 )
Other income (expense):                              
Interest expense   (331 )     (353 )     (668 )     (659 )
Loss on issuance of August 2019 warrants               (1,391 )      
Change in fair value of contingent consideration   (600 )           (363 )      
Other income (expense), net   113       30       272       48  
Total other income (expense), net   (818 )     (323 )     (2,150 )     (611 )
Loss before taxes   (2,824 )     (6,752 )     (9,814 )     (10,669 )
Income Taxes   (46 )           (80 )      
Net loss $ (2,870 )   $ (6,752 )   $ (9,894 )   $ (10,669 )
Basic and diluted net loss per common share: $ (0.02 )   $ (0.06 )   $ (0.07 )   $ (0.10 )
Weighted-average shares outstanding used in computing basic and diluted net loss per common share:   148,096       110,723       144,834       110,707  


MARRONE BIO INNOVATIONS, INC.
Condensed Consolidated Statements of Cash Flows
(In Thousands)

           
  SIX MONTHS ENDED JUNE 30,  
  2020     2019  
Cash flows from operating activities              
Net loss $ (9,894 )   $ (10,669 )
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation and amortization   1,781       903  
Gain on disposal of equipment   (9 )     (6 )
Right of use assets amortization   394       402  
Share-based compensation   1,791       1,164  
Non-cash interest expense   119       145  
Loss on issuance of August 2019 warrants   1,391        
Change in fair value of contingent consideration   (600 )      
Net changes in operating assets and liabilities:              
Accounts receivable   (5,512 )     (4,681 )
Inventories   2,010       (232 )
Prepaid expenses and other assets   167       (453 )
Accounts payable   (2,272 )     622  
Accrued and other liabilities   3,461       2,800  
Lease liability   (397 )     (302 )
Deferred revenue   (172 )     (342 )
Net cash used in operating activities   (7,742 )     (10,649 )
Cash flows from investing activities              
Payment of future contingent consideration in connection with previous asset purchase   (890 )      
Sale of property, plant, equipment   2        
Purchases of property, plant and equipment   (403 )     (185 )
Net cash used in investing activities   (1,291 )     (185 )
Cash flows from financing activities              
Proceeds from secured borrowings   24,724       15,126  
Reductions in secured borrowings   (19,759 )     (12,981 )
Net settlement of options         42  
Financing costs   (64 )      
Exercise of stock options   14        
Proceeds from employee stock purchase plan   129       23  
Exercise of warrants   8,544        
Repayment of debt   (356 )     (126 )
Net cash provided by financing activities   13,232       2,084  
Net increase (decrease) in cash and cash equivalents and restricted cash   4,199       (8,750 )
Cash and cash equivalents and restricted cash, beginning of period   7,812       19,781  
Cash and cash equivalents and restricted cash, end of period $ 12,011     $ 11,031  
               
Supplemental disclosure of cash flow information              
Cash paid for interest $ 565     $ 504  
Supplemental disclosure of non-cash operating activities              
Reclass of restricted stock units in lieu of cash bonus $ 632     $  
Supplemental disclosure of non-cash investing and financing activities              
Property, plant and equipment included in accounts payable and accrued liabilities $ 6     $ 5  

Primary Logo